Fannie Mae, Freddie Mac shares tumble after conservatorship comments
On Thursday, BTIG analyst Sung Ji Nam revised the price target for CareDx, Inc (NASDAQ:CDNA) shares to $30.00, down from the previous $35.00, while reaffirming a Buy rating on the stock. The adjustment followed a 9% decline in CareDx shares after the company reported first-quarter earnings that were consistent with expectations and confirmed its full-year outlook. According to InvestingPro data, the stock has fallen 21.16% year-to-date, despite maintaining strong fundamentals with a healthy current ratio of 3.94.
Nam’s analysis suggests that the market’s reaction to CareDx’s quarterly performance was excessive, likening the 9% drop to a more typical 3% movement in a less volatile market environment. The analyst highlighted the company’s solid fundamentals, noting a 12% year-over-year growth in volumes and an uptick in surveillance volumes, which are considered key indicators of the company’s health. InvestingPro data shows the stock’s beta of 2.18, confirming its higher volatility compared to the market.
The analyst remains optimistic about CareDx’s prospects, describing the stock as undervalued and emphasizing the company’s potential for delivering improved results in the latter half of the year. Nam pointed out that CareDx is trading at approximately 1.6 times the firm’s 2026 revenue estimate of $429 million. This valuation is significantly lower than the average of its peers, which trade around 4.5 times their revenue. InvestingPro’s Fair Value analysis suggests the stock is currently undervalued, with additional metrics showing a favorable PEG ratio of 0.14, indicating attractive growth potential relative to its current valuation. Discover more insights and 10+ additional ProTips about CareDx with an InvestingPro subscription.
CareDx’s current stock price, according to the BTIG analyst, presents a compelling opportunity for investors. The rationale for this perspective is based on the company’s double-digit growth, its dominant position in the market, and robust gross margins of 67.16%. Despite the reduction in the price target, the firm’s reiterated Buy rating suggests continued confidence in CareDx’s business trajectory.
In other recent news, CareDx Inc. reported a strong financial performance for the first quarter of 2025, with earnings per share (EPS) reaching $0.09, surpassing the forecasted loss of $0.19. The company achieved a total revenue of $84.7 million, marking an 18% increase year-over-year. Testing services, a significant revenue driver for CareDx, saw a 15% growth, contributing $61.9 million to the overall revenue. Despite the positive earnings results, the company’s stock experienced a decline, which may have been influenced by broader market conditions or company-specific challenges. CareDx also introduced new transplant testing products, AlloSure Heart and AlloSure Kidney, aimed at expanding its market reach. The company reiterated its revenue guidance for 2025, projecting between $365 million and $375 million, with a target for adjusted EBITDA between $29 million and $33 million. Legal settlements and macroeconomic factors were noted as potential risks, but CareDx maintains a strong position in the transplant testing market. The company also announced a significant initiative to integrate Epic Aura, aiming to streamline the ordering process for healthcare providers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.